Compare BRTX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRTX | MTNB |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.2M |
| IPO Year | 2015 | 2014 |
| Metric | BRTX | MTNB |
|---|---|---|
| Price | $0.40 | $0.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.8M | 312.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | ★ N/A | N/A |
| Revenue | $81,000.00 | ★ $119,750.00 |
| Revenue This Year | $298.39 | N/A |
| Revenue Next Year | $64.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $0.48 |
| 52 Week High | $2.04 | $3.09 |
| Indicator | BRTX | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 65.99 | 75.23 |
| Support Level | $0.20 | $0.55 |
| Resistance Level | $1.20 | $0.98 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 44.86 | 88.66 |
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.